5PSQ-112 Risk assessment of elemental impurties for manufacturing the drug substance (ICH Q3D)

BackgroundThe new ICH Q3D guideline has been recently developed to define and provide a global policy for evaluating and limiting elemental impurities in drug products. Thus, a risk assessment and appropriate control of elemental impurities according to this guideline have become necessary.PurposeTh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A253-A254
Hauptverfasser: Bennis, S, Yachi, L, Ouhaddouch, H, Alami Chentoufi, M, Cheikh, A, Bouatia, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A254
container_issue Suppl 1
container_start_page A253
container_title European journal of hospital pharmacy. Science and practice
container_volume 26
creator Bennis, S
Yachi, L
Ouhaddouch, H
Alami Chentoufi, M
Cheikh, A
Bouatia, M
description BackgroundThe new ICH Q3D guideline has been recently developed to define and provide a global policy for evaluating and limiting elemental impurities in drug products. Thus, a risk assessment and appropriate control of elemental impurities according to this guideline have become necessary.PurposeThe purpose of this study was to explain the risk assessment approach for limiting the presence of elemental impurities in the drug substance.Material and methodsAccording to the guideline ICH Q3D, the identification of elemental impurities of concern and their potential sources of occurrence is realised. The possible levels of elemental impurities were determined based on the published literature and provided information from suppliers. For high-risk elemental impurities, class 1 and class 2A, they we determined by the ICP-MS method. The determined level was then compared with the Permitted Daily Exposure defined in ICH Q3D. All of these assessment results were summarised into one single assessment sheet for each manufacturing step.ResultsThe potential sources of elemental impurities have been identified and several possible sources of class 1 and 2A elemental impurities have been identified. Based on the information in the assessment sheet, an appropriate control point in the manufacturing process and control method were determined. Additionally, the information was included in the assessment sheet to show the control strategy.ConclusionThe risk analysis approach provides a complete risk assessment of potential elemental impurities in the drug substance. All potential sources of elemental impurities of concern for the manufacturing process of the drug substance were mapped together with the control strategy in the proposed assessment sheet. This assessment sheet is considered to also be useful for the life-cycle management of the drug substance.References and/or acknowledgementsDr Mamouni Alaoui Faiçal.No conflict of interest.
doi_str_mv 10.1136/ejhpharm-2019-eahpconf.545
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2189999613</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2189999613</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1265-3e1c8c6ae791b709ab69dc9743f43880603d98b2ff1f26c94c49a59dbcd936f53</originalsourceid><addsrcrecordid>eNo90LtOwzAUBmALgUQFfQcLFhhS7PiSeETl0kqVoFxmYzt2k9JcsOOBjYUX5UlIVcpZzj_8Okf6ADjDaIIx4Vd2XXal8nWSIiwSq8rOtI2bMMoOwChFNEuE4PTwPzN-DMYhVBoxQnJBiRiBN_b4vEwwTn--vp-q8A5VCDaE2jY9bB20G7uNagOruou-r2yArvWwVk10yvTRV80K9qWFhY8rGKIOvWqMhRfz6Qwuyc3lKThyahPs-G-fgNe725fpLFk83M-n14tE45SzhFhscsOVzQTWGRJKc1EYkVHiKMlzxBEpRK5T57BLuRHUUKGYKLQpBOGOkRNwvrvb-fYj2tDLdRt9M7yUKc7FMByTocV2LV2vZeerWvlPiZHcesq9p9x6yr2nHDzJL4Cabjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2189999613</pqid></control><display><type>article</type><title>5PSQ-112 Risk assessment of elemental impurties for manufacturing the drug substance (ICH Q3D)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bennis, S ; Yachi, L ; Ouhaddouch, H ; Alami Chentoufi, M ; Cheikh, A ; Bouatia, M</creator><creatorcontrib>Bennis, S ; Yachi, L ; Ouhaddouch, H ; Alami Chentoufi, M ; Cheikh, A ; Bouatia, M</creatorcontrib><description>BackgroundThe new ICH Q3D guideline has been recently developed to define and provide a global policy for evaluating and limiting elemental impurities in drug products. Thus, a risk assessment and appropriate control of elemental impurities according to this guideline have become necessary.PurposeThe purpose of this study was to explain the risk assessment approach for limiting the presence of elemental impurities in the drug substance.Material and methodsAccording to the guideline ICH Q3D, the identification of elemental impurities of concern and their potential sources of occurrence is realised. The possible levels of elemental impurities were determined based on the published literature and provided information from suppliers. For high-risk elemental impurities, class 1 and class 2A, they we determined by the ICP-MS method. The determined level was then compared with the Permitted Daily Exposure defined in ICH Q3D. All of these assessment results were summarised into one single assessment sheet for each manufacturing step.ResultsThe potential sources of elemental impurities have been identified and several possible sources of class 1 and 2A elemental impurities have been identified. Based on the information in the assessment sheet, an appropriate control point in the manufacturing process and control method were determined. Additionally, the information was included in the assessment sheet to show the control strategy.ConclusionThe risk analysis approach provides a complete risk assessment of potential elemental impurities in the drug substance. All potential sources of elemental impurities of concern for the manufacturing process of the drug substance were mapped together with the control strategy in the proposed assessment sheet. This assessment sheet is considered to also be useful for the life-cycle management of the drug substance.References and/or acknowledgementsDr Mamouni Alaoui Faiçal.No conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2019-eahpconf.545</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Risk assessment</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A253-A254</ispartof><rights>2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2019 2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Bennis, S</creatorcontrib><creatorcontrib>Yachi, L</creatorcontrib><creatorcontrib>Ouhaddouch, H</creatorcontrib><creatorcontrib>Alami Chentoufi, M</creatorcontrib><creatorcontrib>Cheikh, A</creatorcontrib><creatorcontrib>Bouatia, M</creatorcontrib><title>5PSQ-112 Risk assessment of elemental impurties for manufacturing the drug substance (ICH Q3D)</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundThe new ICH Q3D guideline has been recently developed to define and provide a global policy for evaluating and limiting elemental impurities in drug products. Thus, a risk assessment and appropriate control of elemental impurities according to this guideline have become necessary.PurposeThe purpose of this study was to explain the risk assessment approach for limiting the presence of elemental impurities in the drug substance.Material and methodsAccording to the guideline ICH Q3D, the identification of elemental impurities of concern and their potential sources of occurrence is realised. The possible levels of elemental impurities were determined based on the published literature and provided information from suppliers. For high-risk elemental impurities, class 1 and class 2A, they we determined by the ICP-MS method. The determined level was then compared with the Permitted Daily Exposure defined in ICH Q3D. All of these assessment results were summarised into one single assessment sheet for each manufacturing step.ResultsThe potential sources of elemental impurities have been identified and several possible sources of class 1 and 2A elemental impurities have been identified. Based on the information in the assessment sheet, an appropriate control point in the manufacturing process and control method were determined. Additionally, the information was included in the assessment sheet to show the control strategy.ConclusionThe risk analysis approach provides a complete risk assessment of potential elemental impurities in the drug substance. All potential sources of elemental impurities of concern for the manufacturing process of the drug substance were mapped together with the control strategy in the proposed assessment sheet. This assessment sheet is considered to also be useful for the life-cycle management of the drug substance.References and/or acknowledgementsDr Mamouni Alaoui Faiçal.No conflict of interest.</description><subject>Risk assessment</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNo90LtOwzAUBmALgUQFfQcLFhhS7PiSeETl0kqVoFxmYzt2k9JcsOOBjYUX5UlIVcpZzj_8Okf6ADjDaIIx4Vd2XXal8nWSIiwSq8rOtI2bMMoOwChFNEuE4PTwPzN-DMYhVBoxQnJBiRiBN_b4vEwwTn--vp-q8A5VCDaE2jY9bB20G7uNagOruou-r2yArvWwVk10yvTRV80K9qWFhY8rGKIOvWqMhRfz6Qwuyc3lKThyahPs-G-fgNe725fpLFk83M-n14tE45SzhFhscsOVzQTWGRJKc1EYkVHiKMlzxBEpRK5T57BLuRHUUKGYKLQpBOGOkRNwvrvb-fYj2tDLdRt9M7yUKc7FMByTocV2LV2vZeerWvlPiZHcesq9p9x6yr2nHDzJL4Cabjw</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Bennis, S</creator><creator>Yachi, L</creator><creator>Ouhaddouch, H</creator><creator>Alami Chentoufi, M</creator><creator>Cheikh, A</creator><creator>Bouatia, M</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201903</creationdate><title>5PSQ-112 Risk assessment of elemental impurties for manufacturing the drug substance (ICH Q3D)</title><author>Bennis, S ; Yachi, L ; Ouhaddouch, H ; Alami Chentoufi, M ; Cheikh, A ; Bouatia, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1265-3e1c8c6ae791b709ab69dc9743f43880603d98b2ff1f26c94c49a59dbcd936f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Risk assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bennis, S</creatorcontrib><creatorcontrib>Yachi, L</creatorcontrib><creatorcontrib>Ouhaddouch, H</creatorcontrib><creatorcontrib>Alami Chentoufi, M</creatorcontrib><creatorcontrib>Cheikh, A</creatorcontrib><creatorcontrib>Bouatia, M</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bennis, S</au><au>Yachi, L</au><au>Ouhaddouch, H</au><au>Alami Chentoufi, M</au><au>Cheikh, A</au><au>Bouatia, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5PSQ-112 Risk assessment of elemental impurties for manufacturing the drug substance (ICH Q3D)</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2019-03</date><risdate>2019</risdate><volume>26</volume><issue>Suppl 1</issue><spage>A253</spage><epage>A254</epage><pages>A253-A254</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundThe new ICH Q3D guideline has been recently developed to define and provide a global policy for evaluating and limiting elemental impurities in drug products. Thus, a risk assessment and appropriate control of elemental impurities according to this guideline have become necessary.PurposeThe purpose of this study was to explain the risk assessment approach for limiting the presence of elemental impurities in the drug substance.Material and methodsAccording to the guideline ICH Q3D, the identification of elemental impurities of concern and their potential sources of occurrence is realised. The possible levels of elemental impurities were determined based on the published literature and provided information from suppliers. For high-risk elemental impurities, class 1 and class 2A, they we determined by the ICP-MS method. The determined level was then compared with the Permitted Daily Exposure defined in ICH Q3D. All of these assessment results were summarised into one single assessment sheet for each manufacturing step.ResultsThe potential sources of elemental impurities have been identified and several possible sources of class 1 and 2A elemental impurities have been identified. Based on the information in the assessment sheet, an appropriate control point in the manufacturing process and control method were determined. Additionally, the information was included in the assessment sheet to show the control strategy.ConclusionThe risk analysis approach provides a complete risk assessment of potential elemental impurities in the drug substance. All potential sources of elemental impurities of concern for the manufacturing process of the drug substance were mapped together with the control strategy in the proposed assessment sheet. This assessment sheet is considered to also be useful for the life-cycle management of the drug substance.References and/or acknowledgementsDr Mamouni Alaoui Faiçal.No conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2019-eahpconf.545</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A253-A254
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2189999613
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Risk assessment
title 5PSQ-112 Risk assessment of elemental impurties for manufacturing the drug substance (ICH Q3D)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A11%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5PSQ-112%E2%80%85Risk%20assessment%20of%20elemental%20impurties%20for%20manufacturing%20the%20drug%20substance%20(ICH%20Q3D)&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Bennis,%20S&rft.date=2019-03&rft.volume=26&rft.issue=Suppl%201&rft.spage=A253&rft.epage=A254&rft.pages=A253-A254&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2019-eahpconf.545&rft_dat=%3Cproquest_bmj_p%3E2189999613%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2189999613&rft_id=info:pmid/&rfr_iscdi=true